What are the anticoagulation options for intermittent hemodialysis?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Nature Reviews Nephrology

• Publication date

  2011-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrneph.2011.88PMID 21727925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Optimizing the technological and informational relationship of the health care process and of the communication between physician and patient. The impact of Preventive Medicine and social marketing applied in Health Care on youth awareness–Preliminary study

  2011cited by this paper
• What are the options for anticoagulation needs in dialysis for patients with heparin‐induced thrombocytopenia?

  2011cited by this paper
• Citrate anticoagulation using ACD solution A during long‐term haemodialysis

  2011cited by this paper
• A Mathematical Model of Regional Citrate Anticoagulation in Hemodialysis

  2010cited by this paper
• Utility of citrate dialysate in management of acute kidney injury in children

  2010cited by this paper
• Membrane designs and composition for hemodialysis, hemofiltration and hemodialfiltration: past, present and future.

  2010cited by this paper
• Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding.

  2010cited by this paper
• Anticoagulation in acute blood purification for acute renal failure in critical care.

  2010cited by this paper
• Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study.

  2009cited by this paper
• Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis.

  2009cited by this paper
• Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit

  2009cited by this paper
• Superior Outcome of Nafamostat Mesilate as an Anticoagulant in Patients Undergoing Maintenance Hemodialysis with Intracerebral Hemorrhage

  2009cited by this paper
• Review article: Low‐molecular‐weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments

  2009cited by this paper
• The anticoagulant activity of enoxaparin sodium during on‐line hemodiafiltration and conventional hemodialysis

  2009cited by this paper
• The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane.

  2008cited by this paper
• Prolonged half‐life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin‐induced thrombocytopenia

  2008cited by this paper
• Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.

  2008cited by this paper
• Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility?

  2008cited by this paper
• Bivalirudin

  2008cited by this paper
• Low‐molecular‐weight heparin for routine hemodialysis

  2008cited by this paper
• The direct thrombin inhibitor hirudin

  2008cited by this paper
• Heparin‐induced thrombocytopenia – therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4–heparin complexes

  2008cited by this paper
• Contaminated heparin associated with adverse clinical events and activation of the contact system.

  2008cited by this paper
• Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study.

  2008cited by this paper
• Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use.

  2007cited by this paper
• Essentials of anticoagulation in hemodialysis

  2007cited by this paper
• Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding.

  2007cited by this paper
• Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography

  2007cited by this paper
• Anticoagulation options for patients with heparin-induced thrombocytopenia requiring renal support in the intensive care unit.

  2007cited by this paper
• FP357 THE CLINICAL EVALUATION OF LOW DOSE HEPARIN IN HEMODIALYSIS: A PROSPECTIVE STUDY USING THE HEPARIN-COATED AN69 ST MEMBRANE

  2007cited by this paper
• Heparin-induced thrombocytopenia.

  2006cited by this paper
• Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options

  2006cited by this paper
• Maintaining blood flow in the extracorporeal circuit: haemostasis and anticoagulation

  2006cited by this paper
• Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.

  2006cited by this paper
• Anticoagulation options for intermittent haemodialysis.

  2006cited by this paper
• Sustained low-efficiency dialysis (SLED) with prostacyclin in critically ill patients with acute renal failure.

  2006cited by this paper
• Heparin‐induced thrombocytopenia: An uncommon but serious complication of heparin use in renal replacement therapy

  2006cited by this paper
• The management of heparin‐induced thrombocytopenia

  2006cited by this paper
• Assessment of the Heparin-Binding AN69 ST Hemodialysis Membrane: II. Clinical Studies without Heparin Administration

  2005cited by this paper
• Past, present--and future?

  2005cited by this paper
• Safety of Regional Citrate Anticoagulation for Continuous Sustained Low Efficiency Dialysis (C-SLED) in Critically Ill Patients

  2005cited by this paper
• Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin®)

  2005cited by this paper
• Heparin-induced thrombocytopenia: diagnosis and management.

  2004cited by this paper
• Heparin‐induced thrombocytopenia during renal replacement therapy

  2004cited by this paper
• A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease.

  2004cited by this paper
• Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis.

  2004cited by this paper
• Anticoagulation for continuous renal replacement therapy.

  2004cited by this paper
• Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.

  2004cited by this paper
• Citrate anticoagulation and adverse events.

  2003cited by this paper
• Anticoagulation for Intermittent Hemodialysis

  2003cited by this paper
• Heparin-induced thrombocytopenia.

  2002cited by this paper
• Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate.

  2002cited by this paper
• The Acute Dialysis Quality Initiative--part VI: access and anticoagulation in CRRT.

  2002cited by this paper
• Keeping the Circuit Open: Lessons from the Lab

  2002cited by this paper
• Limitations of the Laboratory Monitoring of Heparin Therapy

  2002cited by this paper
• Simplified citrate anticoagulation for high-flux hemodialysis.

  2001cited by this paper
• Anticoagulation for continuous renal replacement therapy

  2001cited by this paper
• Can Nafamostat Mesilate Be Used for Temporary Management of Hemodialysis in a Patient with Heparin-induced Thrombocytopenia (HIT)?

  2001cited by this paper
• Management of Heparin‐Induced Thrombocytopenia During Renal Replacement Therapy

  2001cited by this paper
• Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid

  2000cited by this paper
• Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.

  2000cited by this paper
• Regional citrate anticoagulation in continuous venovenous hemodiafiltration.

  2000cited by this paper
• Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses.

  2000cited by this paper
• Effect of Regional Citrate Anticoagulation on Leukopenia, Complement Activation, and Expression of Leukocyte Surface Molecules during Hemodialysis with Unmodified Cellulose Membranes

  2000cited by this paper
• Dialysate made from dry chemicals using citric acid increases dialysis dose.

  2000cited by this paper
• Effect of anticoagulation on blood membrane interactions during hemodialysis.

  1999cited by this paper
• Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation.

  1999cited by this paper
• Anticoagulation in Patients With Acute Renal Failure Treated With Continuous Renal Replacement Therapies.

  1998cited by this paper
• Citrate anticoagulation does not correct cuprophane bioincompatibility as evaluated by the expression of leukocyte surface molecules.

  1998cited by this paper
• Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis.

  1997cited by this paper
• Anticoagulation strategies for continuous renal replacement therapies: What works?

  1996cited by this paper
• Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation.

  1996cited by this paper
• Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients.

  1996cited by this paper
• Continuous Arteriovenous Hemofiltration and Related Therapies

  1996cited by this paper
• Prognosis in pediatric patients with multiple organ system failure and continuous extracorporeal renal support.

  1995cited by this paper
• Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration

  1994cited by this paper
• Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure.

  1994cited by this paper
• Tight heparin regimen for haemodialysis in children.

  1993cited by this paper
• Antithrombotic Properties of Dermatan Sulphate (MF 701) in Haemodialysis for Chronic Renal Failure

  1992cited by this paper
• Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure

  1991cited by this paper
• Evaluation of platelets and hemostasis during hemodialysis with six different membranes.

  1991cited by this paper
• Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis.

  1991cited by this paper
• [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].

  1990cited by this paper
• Citrate for regional anticoagulation. Effects on blood PO2, ammonia, and aluminum.

  1988cited by this paper
• Severe metabolic alkalosis complicating regional citrate hemodialysis.

  1987cited by this paper
• Heparin elimination and hemostasis in hemodialysis.

  1984cited by this paper
• Lessons from the Lab

  1983cited by this paper
• Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding.

  1983cited by this paper
• Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent.

  1981cited by this paper
• Low-dose heparin in routine hemodialysis monitored by activated partial thromboplastin time.

  1979cited by this paper
• Replacement of renal function by dialysis

  1979cited by this paper
• Venous thrombosis on prosthetic surfaces. Evolution and blood coagulation studies in a nonhuman primate model.

  1974cited by this paper
• Thrombogenic activity of leukocytes.

  1973cited by this paper
• Effect of Adsorbed Proteins on the Wettability of Hydrophilic and Hydrophobic Solids

  1962cited by this paper
• Studies in regional heparinization. II. Artificial-kidney hemodialysis without systemic heparinization; preliminary report of a method using simultaneous infusion of heparin and protamine.

  1956cited by this paper

• Ionized Calcium Before Venous Bubble Trap Strongly Affects Coagulation When Using Calcium‐Containing Dialysate in Regional Citrate Anticoagulation for Intermittent Hemodialysis: A Real‐World Prospective Study

  2025cites this paper
• Integrative anticoagulation of nafamostat mesylate in double plasma molecular adsorption system plus sequential half-dose plasmapheresis for patients with liver failure: a randomised controlled trial protocol

  2025cites this paper
• SOLFA study: a multicenter, open-label, prospective, randomized study to investigate the clotting propensity of asymmetric cellulose triacetate membrane compared to synthetic membranes in on line HDF

  2025cites this paper
• Spatiotemporal evaluation of antithrombotic performance for biomaterials through monitoring β-sheet conformation changes at the blood interface

  2025cites this paper
• Covalent Organic Framework‐Based Porous Anticoagulant Materials for Extracorporeal Blood Circulation

  2025cites this paper
• Nafamostat mesylate in renal replacement therapy: balancing efficacy with emerging risks of hyperkalemia

  2025cites this paper
• Regional citrate anticoagulation for intermittent renal replacement therapy in critically ill patients: a retrospective case-control study

  2025cites this paper
• Carboxybetaine Zwitterionic Coatings on Kidney Dialyzer Components: Surface Characterization and Blood Interactions.

  2025cites this paper
• Low-fouling hemocompatible dialysis membranes realized by surface grown heparin-like hydrogel layer

  2025cites this paper
• A Case Report of a Hemodialysis Patient With Coagulation Factor XI and Factor XII Deficiencies

  2024cites this paper
• Laboratory Monitoring of Heparin Anticoagulation in Hemodialysis: Rationale and Strategies.

  2024cites this paper
• How to Ensure Patency of the Extracorporeal Circuit in Hemodialysis: Global Perspectives.

  2024cites this paper
• Anticoagulation for people receiving long-term haemodialysis.

  2024cites this paper
• Antithrombotic coating with sheltered positive charges prevents contact activation by controlling factor XII–biointerface binding

  2024cites this paper
• Proceedings of a membrane update symposium: advancements, scientific insights, and future trends for dialysis membranes for enhanced clinical outcomes in end stage kidney disease patients

  2024cites this paper
• Early-Stage Protein Adsorption Sequence on Blood-Contacting Surfaces: Answer to Vroman's Question.

  2024cites this paper
• Association between anticoagulation strategy and quality of life in chronic hemodialysis patients

  2023cites this paper
• Regional citrate anticoagulation for replacement therapy in patients with liver failure: A systematic review and meta-analysis

  2023cites this paper
• Pharmacological methods for blood stabilization in the extracorporeal circuit (review of literature)

  2023cites this paper
• Advances in Enhancing Hemocompatibility of Hemodialysis Hollow-Fiber Membranes

  2023cites this paper
• Anticoagulation practices for continuous renal replacement therapy: a survey of physicians from the United States

  2023cites this paper
• Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports

  2023cites this paper
• Anticoagulation polyvinyl chloride extracorporeal circulation catheters for heparin-free treatment.

  2022cites this paper
• Risk assessment of failure during transitioning from in-centre to home haemodialysis

  2022cites this paper
• Effectiveness and Safety of Single Bolus Heparin as Anticoagulant in Hemodialysis

  2022cites this paper
• Why is Intradialytic Hypotension the Commonest Complication of Outpatient Dialysis Treatments?

  2022cites this paper
• Increased risk of dialysis circuit clotting in hemodialysis patients with COVID‐19 is associated with elevated FVIII, fibrinogen and D‐dimers

  2022cites this paper
• Mathematical modelling of post-filter ionized calcium during citrate anticoagulated continuous renal replacement therapy

  2021cites this paper
• Complications and challenges of home hemodialysis: A historical review

  2021cites this paper
• Transient blood thinning during extracorporeal blood purification via the inactivation of coagulation factors by hydrogel microspheres

  2021cites this paper
• Comparison between regional citrate anticoagulation and heparin for intermittent hemodialysis in ICU patients: a propensity score-matched cohort study

  2021cites this paper
• A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis

  2021cites this paper
• Multi‐response optimization of shrinkage, clamp force, and part weight in simulated injection molding process of a dialysis micro‐filter

  2021cites this paper
• Heparin-free regional anticoagulation of haemodialysis filters with calcium-free dialysate: is citrate mandatory?

  2021cites this paper
• Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation.

  2021cites this paper
• The Effect of Preparing Dialysis Machine Using Normal Saline-Heparin on the Dialysis Adequacy of Hemodialysis Patients: A Crossover, Two-Group, and Randomized Clinical Trial

  2021cites this paper
• Dialyzer Performance During Hemodialysis Without Systemic Anticoagulation Using a Heparin-Grafted Dialyzer Combined With a Citrate-Enriched Dialysate: Results of the Randomized Crossover Noninferiority EVOCIT Study.

  2021cites this paper
• Highlights from the American society of hematology conference 2020

  2021cites this paper
• Expanded hemodialysis: Is anticoagulation of the dialysis circuit different from online hemodiafiltration and high‐flux hemodialysis?

  2021cites this paper
• Anticoagulation in hemodialysis: A narrative review

  2020cites this paper
• Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration

  2020cites this paper
• Plasma levels of enoxaparin oligosaccharides, antifactor-Xa and thrombin generation in patients undergoing haemodialysis.

  2020cites this paper
• Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during hemodialysis.

  2020cites this paper
• Comparison of using fractionated and unfractionated heparins after primary hip and knee arthroplasty in patients receiving programmed hemodialysis

  2020cites this paper
• Platelets in Advanced Chronic Kidney Disease: Two Sides of the Coin

  2020cites this paper
• Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study

  2020cites this paper
• Возможности использования фракционированных и нефракционированных гепаринов после первичного эндопротезирования тазобедренного и коленного суставов у пациентов, получающих программный гемодиализ

  2020cites this paper
• Anticoagulant strategies for the patient with chronic kidney disease.

  2020cites this paper
• Efficacy and tolerance of sustained low-efficiency dialysis with calcium-free citrate-containing dialysate anticoagulation

  2020cites this paper
• Covalent biofunctionalisation of the inner surfaces of a hollow fibre capillary bundle using packed bed plasma ion implantation.

  2020cites this paper
• Anticoagulant dialyzer with enhanced Ca2+ chelation and hydrophilicity for heparin free hemodialysis

  2020cites this paper
• A critical review of recent advances in hemodialysis membranes hemocompatibility and guidelines for future development

  2020cites this paper
• Renal Replacement Therapy in Adult Patients After Cardiac Surgery.

  2019cites this paper
• Proteins adsorbed to a polysulfone hemodialysis membrane under heparin and citrate anticoagulation regimens.

  2019cites this paper
• Danaparoid use for haemodialysis in a morbidly obese patient with heparin-induced thrombocytopenia - Need for a higher than recommended weight-based dosing.

  2019cites this paper
• Principles of Anticoagulation in Extracorporeal Circuits

  2019cites this paper
• Branch retinal artery occlusion in the untreated contralateral eye following aflibercept injections during heparin treatment: Possible contribution of a heparin-induced thrombocytopenia-like condition

  2019cites this paper
• Heparin: An essential drug for modern medicine.

  2019cites this paper
• Safety and Efficacy of Tinzaparin Anticoagulation during Nocturnal Hemodialysis

  2019cites this paper
• Mathematical model of calcium exchange during haemodialysis using a citrate containing dialysate.

  2018cites this paper
• Platelet activation and clotting cascade activation by dialyzers designed for high volume online hemodiafiltration

  2018cites this paper
• The Allergen Der p3 from House Dust Mite Stimulates Store-Operated Ca2+ Channels and Mast Cell Migration through PAR4 Receptors.

  2018cites this paper
• Heparin‐free renal replacement therapy for chronic hemodialyzed patients at high risk for bleeding: a comparison of on‐line predilution hemodiafiltration with conventional hemodialysis

  2018cites this paper
• Évaluation de la sécurité des héparines de bas poids moléculaire en hémodialyse au Québec : une étude de cohorte rétrospective

  2018cites this paper
• Acute effects of haemodialysis on circulating microparticles

  2018cites this paper
• Paciente con trombocitopenia trombótica inducida por heparina en hemodiálisis: abordaje de la anticoagulación del circuito

  2018cites this paper
• Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute Care Inpatient Practice

  2017cites this paper
• Heparin-Free Prolonged Intermittent Hemodialysis Using Calcium-Free Citrate Dialysate in Critically Ill Patients

  2017cites this paper
• Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005–13. Nephrology Dialysis Transplantation , 32 (4), 692-698.

  2017cites this paper
• Filter Size Not the Anticoagulation Method is the Decisive Factor in Continuous Renal Replacement Therapy Circuit Survival

  2017cites this paper
• Correlation between activated partial thromboplastin time and anti‐Xa activity in patients who received low‐molecular weight heparin as anticoagulation for haemodialysis

  2017cites this paper
• A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CiTED study

  2017cites this paper
• Fatal Dialysis Vascular Access Hemorrhage.

  2017cites this paper
• A simple and novel technique for regional citrate anticoagulation during intermittent hemodialysis may obviate the need for calcium monitoring

  2017cites this paper
• Chapter 14 – Methods of Hemodialysis Anticoagulation

  2017cites this paper
• Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials

  2016cites this paper
• Extracorporeal support for patients with acute and acute on chronic liver failure

  2016cites this paper
• Outcomes Associated with a Heparin-Free Hemodialysis Protocol and Review of the Literature

  2016influential citation
• Clinical safety and performance of VIVIA: a novel home hemodialysis system

  2016cites this paper
• Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort

  2016cites this paper
• Thrombosis and anticoagulation in the setting of renal or liver disease.

  2016influential citation
• Anticoagulation for renal replacement therapy for patients with acute kidney injury.

  2016cites this paper
• Pharmacology of Heparin and Related Drugs

  2016cites this paper
• Anticoagulation in Chronic Hemodialysis: Progress Toward an Optimal Approach

  2015influential citation
• Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial

  2015cites this paper
• Heparinización directa del paciente frente a heparinización del circuito extracorpóreo en hemodiálisis: estudio comparativo

  2015cites this paper
• Preparation and characterization of a thrombin inhibitor grafted polyethersulfone blending membrane with improved antithrombotic property

  2015cites this paper
• Urokinase can reduce heparin dose in patients with hypercoagulable states during hemodialysis

  2015cites this paper
• Major bleeding in hemodialysis patients using unfractionated or low molecular weight heparin: a single-center study.

  2015cites this paper
• Anticoagulation for people receiving long‐term haemodialysis

  2015cites this paper
• Effect of switching unfractionated heparin to low-molecular-weight heparin on serum potassium in hemodialysis patients.

  2014cites this paper
• Review Article Plasmapheresis- Review Article

  2014cites this paper
• Plasmapheresis- Review Article

  2014cites this paper
• Heparin Use in Hemodialysis Patients following Gastrointestinal Bleeding

  2014cites this paper
• Heparin-coated dialyzer membranes: is non-inferiority good enough?

  2014cites this paper
• Inpatient hemodialysis without anticoagulation in adults

  2014influential citation
• Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin.

  2014cites this paper
• Haemostasis in chronic kidney disease.

  2014influential citation
• Anticoagulation in chronic kidney disease patients—the practical aspects

  2014cites this paper
• Anticoagulation Strategies in Venovenous Hemodialysis in Critically Ill Patients: A Five-Year Evaluation in a Surgical Intensive Care Unit

  2014cites this paper